The pharmaceutical industry is active in investment and financing, and these fields are attracting attention

【Pharmaceutical Network Market Analysis】The support of many favorable policies, coupled with the entry of a large amount of capital, is accelerating the development of the pharmaceutical industry to high-quality innovation
.
Affected by this, the activity of pharmaceutical investment and financing has also begun to continue to heat up, and it is not uncommon
for the current financing amount to reach hundreds of millions of yuan.
On November 14, Shanghai Bangyao Biotechnology Co.
, Ltd.
, which focuses on gene and cell therapy, announced the completion of a series B financing
of more than RMB 200 million.
After this round of financing, Bangyao Biotech will continue to promote the transformation and landing of cell and gene drugs, and increase efforts to further accelerate the global R&D layout, help the development of global life sciences, and bring hope
to patients with genetic diseases, malignant tumors and autoimmune system diseases around the world.
Prior to this, Zenash Biologics also announced a $118 million Series B financing
.
This round of financing was led by Enavate Sciences, with participation from other investors such as Vivo Capital
.
It is understood that this round of financing will be used to support the clinical trial of the company's main drug candidate, obexelimab, and to promote the company's other global autoimmune disease programs into clinical development
in 2023.
obexelimab is a CD19 x FcƳRIIB bispecific antibody introduced by Zenash Biologics from Xencor, and Zenash Biologics now has exclusive global development, manufacturing and commercialization rights
for the drug.
In fact, financing in the pharmaceutical industry is very common, and it has always been a bright landscape in the pharmaceutical field because it is conducive to further optimizing the layout of the R&D pipeline
.
It is worth noting that at present, on the whole, innovative pharmaceutical enterprises and biomedical industries are particularly favored
by capital.
First of all, from the perspective of financing rounds, the financing rounds of enterprises involved in the large category of innovative drugs are relatively high; The industry believes that this may indicate that the pharmaceutical industry is ushering in a new round of development, and start-up innovative pharmaceutical companies are also the obvious main force
.
It is worth noting that in the category of innovative drugs, immunotherapy drugs, gene therapy drugs, and antibody drugs are the hot tracks that capital focuses on; From the perspective of disease fields, tumor is still a hot investment and financing disease field
.
In this regard, analysts said that financing data has a predictive effect on the secondary market, and the strategic decision-making of enterprises through the analysis of the direction of capital also has an enlightening effect, so enterprises focusing on the above areas may have good performance
in the capital market.
In addition, in recent years, the domestic biomedical field is also ushering in "spring", and the activity of financing is continuing to rise
.
The data shows that from 2017 to 2021, the number of investment and financing events and transaction amounts in China's biomedical field continued to rise
.
In 2021, the number of investment and financing events reached 5,061, with a transaction amount of 131.
85 billion yuan
.
Industry analysts believe that the biopharmaceutical industry has the characteristics of high investment, long cycle, high risk and high added value, resulting in a strong
dependence of the biopharmaceutical industry on core technology research and development, high-level talents, and innovation research and development investment.
Therefore, the entry of a large amount of capital will undoubtedly promote the acceleration of high-quality innovation and development of the biomedical industry
.
In the future, affected by this, a number of internationally competitive Chinese biomedical innovation enterprises are expected to continue to emerge and contribute to the innovation and development of China's biomedical industry
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.